Patents Assigned to The Rogosin Institute
  • Patent number: 8741637
    Abstract: The invention relates to the use of encapsulates of cancer cells, in agarose coated, agarose containing beads, for isolating chemotherapeutic resistant cells which have at least one stem cell property, such as expression of OCT4. The cells thus isolated are also a feature of the invention, as is a method for screening for potential therapeutic agents.
    Type: Grant
    Filed: November 22, 2011
    Date of Patent: June 3, 2014
    Assignee: The Rogosin Institute, Inc.
    Inventors: Lawrence Gazda, Barry Smith
  • Patent number: 8518394
    Abstract: The invention describes the manufacture and use of secretory cell containing bead structures that are coated with agarose. The beads, which are preferably 4 mm-12 mm in diameter, and which preferably contain islets, are made of a particular agarose, i.eagarose which has a sulfate content of less than 0.2 wt % but greater than zero, a pyruvate content of 0-0.1 wt %, and a Kjeldahl nitrogen content of 0-0.04 wt %. The gels found from the agarose exhibit a gel strength of at least 1200 g/cm2 (1.0 wt % concentration), substantial absence of DNA binding in 0.07 M or less tris acetate buffer, and an EEO at 1.0 wt % agarose concentration of 0.05 or less.
    Type: Grant
    Filed: September 14, 2006
    Date of Patent: August 27, 2013
    Assignee: The Rogosin Institute
    Inventors: Lawrence Gazda, Barry Smith
  • Patent number: 7838291
    Abstract: The invention relates to the stem cells, embryonic stem cells in particular. It has been found that, when these stem cells are entrapped such that their proliferation is inhibited, they produce material which inhibits the proliferation of other, non-entrapped cells, including stem cells and neoplastic and/or hyperproliferative, but otherwise normal cells. It has also been found that entrapped cancer cells will produce material which inhibits the proliferation of stem cells. Further, it has been found that the entrapment of the stem cells inhibits their differentiation and thus the entrapment process can serve as a long-term storage device for maintaining the undifferentiated state of at least a portion of the entrapped cells.
    Type: Grant
    Filed: August 10, 2007
    Date of Patent: November 23, 2010
    Assignee: The Rogosin Institute
    Inventors: Bryan Conn, Barry Smith, Albert L. Rubin, Kurt Stenzel
  • Patent number: 7413871
    Abstract: The invention relates to a method for evaluating a pancreas as a source of therapeutically useful islets. A scoring system is set forth whereby 5 criteria are listed. If three criteria are positive, then the pancreas is a suitable source of therapeutically useful islets.
    Type: Grant
    Filed: November 14, 2005
    Date of Patent: August 19, 2008
    Assignee: The Rogosin Institute
    Inventors: Lawrence Gazda, Barry Smith, Albert Rubin
  • Patent number: 7297331
    Abstract: Compositions of matter are described which contain restricted cancer cells. When so restricted, the cells produce an unexpectedly high amount of material which suppresses cancer cell proliferation. The phenomenon crosses cancer type and species lines. Processes for making these compositions, and their use, are also described.
    Type: Grant
    Filed: August 16, 2004
    Date of Patent: November 20, 2007
    Assignee: The Rogosin Institute
    Inventors: Shirin Asina, Kanti Jain, Albert L. Rubin, Barry Smith, Kurt Stenzel
  • Patent number: 7041504
    Abstract: Compositions of matter are described which contain restricted cancer cells. When so restricted, the cells produce an unexpectedly high amount of material which suppresses cancer cell proliferation. The phenomenon crosses cancer type and species lines. Processes for making these compositions, and their use, are also described.
    Type: Grant
    Filed: December 12, 2000
    Date of Patent: May 9, 2006
    Assignee: The Rogosin Institute
    Inventors: Shirin Asina, Kanti Jain, Albert L. Rubin, Barry Smith, Kurt Stenzel
  • Patent number: 6818230
    Abstract: Compositions of matter are described which contain restricted cancer cells. When so restricted, the cells produce an unexpectedly high amount of material which suppresses cancer cell proliferation. The phenomenon crosses cancer type and species lines. Processes for making these compositions, and their use, are also described.
    Type: Grant
    Filed: January 3, 2003
    Date of Patent: November 16, 2004
    Assignee: The Rogosin Institute
    Inventors: Shirin Asina, Kanti Jain, Albert L. Rubin, Barry Smith, Kurt Stenzel
  • Patent number: 6808705
    Abstract: Compositions of matter are described which contain restricted cancer cells. When so restricted, the cells produce an unexpectedly high amount of material which suppresses cancer cell proliferation. The phenomenon crosses cancer type and species lines. Processes for making these compositions, and their use, are also described.
    Type: Grant
    Filed: January 3, 2003
    Date of Patent: October 26, 2004
    Assignee: The Rogosin Institute
    Inventors: Shirin Asina, Kanti Jain, Albert L. Rubin, Barry Smith, Kurt Stenzel
  • Patent number: 6780643
    Abstract: Compositions of matter are described which contain restricted cancer cells. When so restricted, the cells produce an unexpectedly high amount of material which suppresses cancer cell proliferation. The phenomenon crosses cancer type and species lines. Processes for making these compositions, and their use, are also described.
    Type: Grant
    Filed: December 12, 2000
    Date of Patent: August 24, 2004
    Assignee: The Rogosin Institute
    Inventors: Shirin Asina, Kanti Jain, Albert L. Rubin, Barry Smith, Kurt Stenzel
  • Patent number: 6303151
    Abstract: A material for suppressing proliferation of cancer cells is produced by entrapping cancer cells in a selectively-permeable structure such as a bead, and culturing the entrapped cells in a culture medium. Entrapment restricts growth of the cancel cells during culturing and causes the cells to produce in the culture medium a material having a molecular weight of at least about 30 kd as measured by filtration that suppresses proliferation of cancer cells. The material is separated from the culture medium by filtering the medium through a filter that separates material having a molecular weight of at least about 30 kd from material having a molecular weight of less than 30 kd. The structure that entraps the cells may contain 10,000 to 500,000 cells. The material or the structure containing the entrapped cells that produce the material can be administered to a subject to suppress cancer cell proliferation.
    Type: Grant
    Filed: November 9, 1999
    Date of Patent: October 16, 2001
    Assignee: The Rogosin Institute
    Inventors: Shirin Asina, Kanti Jain, Albert L. Rubin, Barry Smith, Kurt Stenzel
  • Patent number: 5888497
    Abstract: Implantable beads which contain agarose and optionally collagen, and are coated with agarose have incorporated within cells which produce diffusible biological products. The beads may be used as implants to modulate a recipient's immune response. The beads may also be used in an in vitro context to encourage specific types of cells to grow, to produce desirable products in culture, or to suppress growth of certain cells. The implants may also suppress growth of certain cells following administration to a subject. Cancer cells such as renal cancer cells when restricted by being entrapped in the beads produce more of a material that suppresses cancer cell proliferation.
    Type: Grant
    Filed: November 7, 1996
    Date of Patent: March 30, 1999
    Assignee: The Rogosin Institute
    Inventors: Kanti Jain, Albert L. Rubin, Shirin Asina, Barry Smith, Kurt Stenzel
  • Patent number: 5674855
    Abstract: Treatment and prophylaxis of endotoxin caused toxicity is disclosed. This is accomplished by administering phospholipid containing compositions to the subject. The compositions are protein and peptide free, and may contain triglycerides, or other polar or neutral lipids.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 7, 1997
    Assignee: The Rogosin Institute
    Inventors: Daniel M. Levine, Thomas S. Parker, Albert L. Rubin, Bruce R. Gordon, Stuart D. Saal
  • Patent number: 5643569
    Abstract: Biological agents such as secretory cells are encapsulated in a hydrophilic gel made of agarose or collagen-agarose and gelatin sponge-agarose combinations. In a preferred embodiment, semi-solid beads are formed from a suspension containing collagen, agarose and secretory cells such as pancreatic islets, the collagen is polymerized to form solid, agarose-collagen beads and the solid beads are coated with agarose. Coating is preferably by rolling the solid beads in about 5-10% agarose, contacting the rolled beads with mineral oil and washing oil from the beads. Beads containing secretory cells can be transplanted into a mammal to treat a condition caused by impaired secretory cell function.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 1, 1997
    Assignee: The Rogosin Institute
    Inventors: Kanti Jain, Albert L. Rubin, Barry H. Smith
  • Patent number: 5614507
    Abstract: Protein and peptide free compositions are described, which are useful in treating endotoxemia. The compositions contain a phospholipid and a neutral lipid, preferably phosphatidylcholine and triglyceride.
    Type: Grant
    Filed: May 2, 1995
    Date of Patent: March 25, 1997
    Assignee: The Rogosin Institute
    Inventors: Thomas S. Parker, Daniel M. Levine, Albert L. Rubin, Bruce R. Gordon, Stuart D. Saal
  • Patent number: 5587366
    Abstract: Treatment and prophylaxis of endotoxin caused toxicity is disclosed. This is accomplished by administering phospholipid containing compositions to the subject. The compositions are protein and peptide free, and may contain triglycerides, or other polar or neutral lipids.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 24, 1996
    Assignee: The Rogosin Institute
    Inventors: Thomas S. Parker, Daniel M. Levine, Albert L. Rubin, Bruce R. Gordon, Stuart D. Saal
  • Patent number: 5506218
    Abstract: Treatment and prophylaxis of endotoxin caused toxicity is disclosed. This is accomplished by administering phospholipid containing compositions to the subject. The compositions are protein and peptide free, and may contain triglycerides, or other polar or neutral lipids.
    Type: Grant
    Filed: August 10, 1994
    Date of Patent: April 9, 1996
    Assignee: The Rogosin Institute
    Inventors: Thomas S. Parker, Daniel M. Levine, Albert L. Rubin, Bruce R. Gordon, Stuart D. Saal
  • Patent number: 5344822
    Abstract: Treatment and prophylaxis of endotoxin caused toxicity is disclosed. This is accomplished by administering a lipid into which the endotoxin of concern is associated, preferably together with a peptide which is not an apolipoprotein. Preferably, the two components are administered in the form of a reconstituted particle, although this is by no means required.
    Type: Grant
    Filed: August 12, 1992
    Date of Patent: September 6, 1994
    Assignee: The Rogosin Institute
    Inventors: Daniel M. Levine, Thomas S. Parker, Albert L. Rubin
  • Patent number: RE39542
    Abstract: Biological agents such as secretory cells are encapsulated in a hydrophilic gel made of agarose or collagen-agarose and gelatin sponge-agarose combinations. In a preferred embodiment, semi-solid beads are formed from a suspension containing collagen, agarose and secretory cells such as pancreatic islets, the collagen is polymerized to form solid, agarose-collagen beads and the solid beads are coated with agarose. Coating is preferably by rolling the solid beads in about 5-10% agarose, contacting the rolled beads with mineral oil and washing oil from the beads. Beads containing secretory cells can be transplanted into a mammal to treat a condition caused by impaired secretory cell function.
    Type: Grant
    Filed: January 2, 2003
    Date of Patent: April 3, 2007
    Assignee: The Rogosin Institute
    Inventors: Kanti Jain, Albert L. Rubin, Barry Smith
  • Patent number: RE38027
    Abstract: Biological agents such as secretory cells are encapsulated in a hydrophilic gel made of agarose or collagen-agarose and gelatin sponge-agarose combinations. In a preferred embodiment, semi-solid beads are formed from a suspension containing collagen, agarose and secretory cells such as pancreatic islets, the collagen is polymerized to form solid, agarose-collagen beads and the solid beads are coated with agarose. Coating is preferably by rolling the solid beads in about 5-10% agarose, contacting the rolled beads with mineral oil and washing oil from the beads. Beads containing secretory cells can be transplanted into a mammal to treat a condition caused by impaired secretory cell function.
    Type: Grant
    Filed: June 30, 1999
    Date of Patent: March 11, 2003
    Assignee: The Rogosin Institute
    Inventors: Kanti Jain, Albert L. Rubin, Barry Smith
  • Patent number: RE40555
    Abstract: Biological agents such as secretory cells are encapsulated in a hydrophilic gel made of agarose or collagen-agarose and gelatin sponge-agarose combinations. In a preferred embodiment, semi-solid beads are formed from a suspension containing collagen, agarose and secretory cells such as pancreatic islets, the collagen is polymerized to form solid, agarose-collagen beads and the solid beads are coated with agarose. Coating is preferably by rolling the solid beads in about 5-10% agarose, contacting the rolled beads with mineral oil and washing oil from the beads. Beads containing secretory cells can be transplanted into a mammal to treat a condition caused by impaired secretory cell function.
    Type: Grant
    Filed: November 1, 2004
    Date of Patent: October 28, 2008
    Assignee: The Rogosin Institute
    Inventors: Kanti Jain, Albert L. Rubin, Barry Smith